Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
Rhea-AI Summary
Azitra (NYSE American: AZTR) announced it has received written notification from NYSE American that it has regained compliance with all continued listing standards set forth in Part 10 of the NYSE American Company Guide, resolving previously disclosed deficiencies under Sections 1003(a)(ii) and 1003(a)(iii).
As a result, the ".BC" below‑compliance indicator will no longer be disseminated and Azitra will be removed from NYSE American’s noncompliant issuers list. The company will remain subject to continued listing monitoring, and a repeat deficiency within 12 months could lead to truncated compliance procedures or immediate delisting proceedings.
Positive
- Regained NYSE American compliance with all continued listing standards in Part 10
- Previous deficiencies resolved under Sections 1003(a)(ii) and 1003(a)(iii)
- “.BC” indicator removed and AZTR taken off noncompliant issuers list
Negative
- Continued monitoring by NYSE Regulation despite restored compliance
- 12‑month risk window where renewed noncompliance could trigger accelerated or immediate delisting action
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Q2 earnings report | Neutral | +3.7% | Q2 results showed a larger net loss alongside pipeline updates and higher cash. |
| Jul 15 | ATR-COSF clinical data | Positive | +5.0% | Ex vivo repeat-dose and elasticity findings supported ATR-COSF cosmetic formulation development. |
| Jul 15 | ATR-COSF data correction | Positive | +5.0% | Corrected ex vivo results detailed elasticity gains and non-irritating hydrogel testing. |
| Jun 17 | Strategic reorientation update | Positive | +10.3% | Strategic reorientation emphasized nearer-term milestones, financing resources, and expanded cosmetic initiatives. |
| Jun 16 | Conference presentation notice | Neutral | +10.3% | The company scheduled a BIO presentation covering pipeline progress and cosmetic protein initiatives. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or mixed announcements were followed by positive 24-hour reactions, although the neutral conference notice also preceded a gain.
Key Terms
below compliance regulatory
continued listing standards regulatory
delisting proceedings regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
In a letter dated August 19, 2026, NYSE Regulation informed Azitra that the Company has resolved the previously disclosed continued listing deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. As a result, the "below compliance" (".BC") indicator will no longer be disseminated, and Azitra will be removed from the list of NYSE American noncompliant issuers on the NYSE American's website. The Company will remain subject to NYSE Regulation's continued listing monitoring procedures and remains committed to maintaining strong financial discipline and governance going forward. In accordance with Section 1009(h) of the NYSE American Company Guide, if the Company is again determined to be below any of the continued listing standards within 12 months of the date of the letter, NYSE American will examine the relationship between the two incidents of noncompliance and re-evaluate the Company's method of financial recovery from the first incident. NYSE American will then take the appropriate action, which, depending on the circumstances, may include truncating the compliance procedures described Section 1009 of the NYSE American Company Guide or immediately initiating delisting proceedings.
"We are pleased to have resolved this matter and regained full compliance with the NYSE American continued listing standards," said Francisco Salva, Chief Executive Officer of Azitra. "Looking ahead, we remain focused on building momentum across our pipeline and are excited to advance our ATR-COSF and ATR-04 programs as we work to realize the potential of our platform and create value for shareholders."
About Azitra, Inc.
Azitra, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and novel products across therapeutics, cosmeceuticals and biotechnology applications. The Company's portfolio is highlighted by ATR-COSF, a recombinant protein technology designed for cosmetic and skincare applications, and ATR-04, an investigational live biotherapeutic for EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFR inhibitor-associated rash, which impacts approximately 150,000 people in the U.S. Azitra is also advancing additional recombinant protein initiatives designed to support biotechnology research and manufacturing applications. Azitra's technology platforms combine engineered proteins, topical live biotherapeutics, artificial intelligence, and a proprietary microbial library to develop differentiated products for consumer, research and healthcare markets. For more information, please visit https://azitrainc.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of (i) our potential resumption and expected timing of initial safety data and topline results for the Phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, (iv) statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies, including our cosmeceutical strategy and our recombinant protein platform, (v) the expected timing of our planned human cosmetic application study for ATR-COSF, and (vi) statements regarding our strategy plans and priorities, including those outlined in our recent shareholder letter.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: statements regarding the Company's ability to maintain compliance with NYSE American's continued listing standards; the timing of clinical trials and their results; we may experience delays in the provision of initial safety data and topline results for ATR-COSF, our recombinant protein platform, ATR-12 and ATR-04 and, if we do, such data and results may not be favorably received; the safety and efficacy of our product candidates; possible delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on February 27, 2026 and our quarterly reports on Form 10-Q filed on May 13, 2026 and August 12, 2026 with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
231-632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-regains-compliance-with-nyse-american-continued-listing-standards-302856928.html
SOURCE Azitra, Inc.